Last reviewed · How we verify
Rescue therapy
Rescue therapy involves providing immediate relief or intervention to prevent or mitigate a worsening condition.
Rescue therapy involves providing immediate relief or intervention to prevent or mitigate a worsening condition. Used for Acute myocardial infarction, Status epilepticus, Severe asthma exacerbation.
At a glance
| Generic name | Rescue therapy |
|---|---|
| Sponsor | National Cheng-Kung University Hospital |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of rescue therapy can vary depending on the specific condition being treated, but it often involves administering a medication or treatment to rapidly stabilize or improve the patient's condition. This can include medications to manage acute symptoms, prevent complications, or restore normal bodily functions.
Approved indications
- Acute myocardial infarction
- Status epilepticus
- Severe asthma exacerbation
Common side effects
- Hypotension
- Bradycardia
- Respiratory depression
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis (PHASE2)
- Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rescue therapy CI brief — competitive landscape report
- Rescue therapy updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI